Compare Recursion Pharmaceuticals Inc (RXRX) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B), while Tencent Music Entertainment Group - ADR trades at $8.44 (market cap $16.09B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 8.9× Recursion Pharmaceuticals Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TME | |
|---|---|---|
Market Cap | $1.81B | $16.09B |
Sector | Health | Media |
52-Week High | $6.79 | $26.36 |
52-Week Low | $2.84 | $8.16 |
Enterprise Value | $1.33B | $14.05B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
TME stock trades at $9.90, up 3.88% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $8.9 billion (up 6% year-over-year) and net profit of $2.5 billion, beating EPS estimates. Financials show strong profitability with a net income margin of 26.28% and a P/E ratio of 10.29, indicating potential undervaluation. Recent news highlights mixed quarterly performance with revenue growth slowing but profit beating expectations.
The outlook for TME is cautiously optimistic, supported by solid fundamentals and bullish analyst sentiment, but risks include intensifying competition, user churn, and AI-related copyright issues. Upside potential exists from premium membership growth and ecosystem integration, though near-term volatility may persist due to market conditions and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
